This brochure highlights Cyagen's integrated oncology CRO platform, supporting end-to-end translational research from model development to in vivo efficacy and molecular validation. Featuring advanced immune-humanized mouse models and diverse oncology systems, we enable robust tumor biology and drug evaluation studies. Accelerate your preclinical research with our reliable and scalable solutions.

This Frost & Sullivan 2026 Blue Book provides a comprehensive analysis of the global and Chinese antibody therapeutics industry. It covers market scale, technology evolution, and supply chain localization, highlighting key enablers like Cyagen to offer strategic guidance for stakeholders.

This brochure details Cyagen's one-stop Adeno-Associated Virus (AAV) solutions tailored for gene therapy, neuroscience, ophthalmology, and metabolic disease research. This brochure highlights our high-titer in-stock products and custom AAV packaging services. Discover our AI-engineered capsid variants capable of efficiently crossing the blood-brain barrier (BBB) for robust central nervous system (CNS) transduction.Accelerate your in vivo disease modeling and drug evaluation workflows.

JPM 2026 Insights by Cyagen: AI Transformation, Globalization 2.0, and Emerging Innovations in Core Modalities from Next-Gen ADCs to Degrader-Antibody Conjugates (DACs)

This white paper highlights Cyagen’s One-Stop Ophthalmology CRO Solutions, an end-to-end platform providing specialized HUGO-GT humanized models, 90%-success-rate surgical injections, and comprehensive efficacy evaluations to support every stage of ocular gene therapy development and IND filings.

This white paper aims to systematically analyze the current status and trends of the global and Chinese BsAb markets, explore key technological bottlenecks in depth, and introduce how Cyagen Biosciences leverages its HUGO-Ab™ series of fully human antibody mice.